| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8606 | Alvimopan monohydrate | Alvimopan(LY 246736; ADL 8-2698) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery. |
|
| DC8605 | Alvimopan dihydrate | Alvimopan(LY 246736; ADL 8-2698) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery. |
|
| DC10209 | ALW-II-41-27 Featured | ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor, used for cancer treatment. |
|
| DC23849 | ALW-II-49-7 | ALW-II-49-7 (DDR2-IN-1) is a potent, selective DDR2 inhibitor with IC50 of 18.6 nM, also shows ability to inhibit DDR1 and Ephrin-family kinases (IC50=40 nM for EphB2). |
|
| DC11840 | ALX-1393 | ALX-1393 (ALX 1393, ALX1393) is a potent, specific GlyT2 inhibitor with Ki of <1 uM. |
|
| DC23604 | ALX-5407 hydrochloride Featured | ALX-5407 is a potent, selective, orally active inhibitor of GlyT1 glycine transporter with IC50 of 3 nM. |
|
| DC11301 | ALZ-801 Featured | ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease. |
|
| DC22431 | AM432 sodium | AM 432 is potent, selective, orally active prostaglandin D2 receptor (DP2/CRTH2) antagonist with binding IC50 of 6 nM for hDP2. |
|
| DC11182 | AM-0216 | AM-0216 (Amgen16) is a highly potent inhibitor of NF-κB inducing Kinase (NIK) with Ki of 2 nM, selectively decrease viability of MMCLs in which NFkB activity is NIK-dependent. |
|
| DC11181 | AM-0561 | AM-0561 (AM0561) is a highly potent inhibitor of NF-κB inducing Kinase (NIK) with Ki of 0.3 nM.. |
|
| DC8621 | AM095 Featured | AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively. |
|
| DC8622 | AM095 free acid Featured | AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively. |
|
| DC8765 | AM251 Featured | AM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors; also potent GPR55 agonist (EC50 = 39 nM). |
|
| DC23485 | AM-5262 | AM-5262 is a potent full GPR40 (FFA1) agonist with EC50 of 81 nM. |
|
| DC23435 | AM-6226 | AM-6226 (AM6226) is a potent, selective, orally bioavailable GPR40 (FFA1) full agonist with EC50 of 0.12 uM. |
|
| DC11552 | AM-6538 | AM-6538 (AM6538) is a potent, selective cannabinoid receptor CB1 antagonist with Ki of 5.1 nM.. |
|
| DC9447 | AM679 | AM679 is a potent and selective FLAP inhibitor with IC50s of 2.2 nM/0.6 nM/154 nM for FLAP binding/hLA/hWB respectively. |
|
| DC11221 | AM9405 | AM9405 (AM-9405) is novel potent, peripherally active cannabinoid type 1 (CB1) and 5-HT3 receptor agonist, inhibits the EFS-induced twitch contraction of the ileum and the colon with IC50 of 0.076 and 45.71 nM, respectively. |
|
| DC20792 | Amelubant | Amelubant (BIIL284) is a potent, long-acting, orally active leukotriene B4 (LTB4) receptor antagonist, inhibits LTB4-induced mouse ear inflammation with ED50 of 0.008 mg/kg (p.o.). |
|
| DC12002 | AMG 580 | AMG 580 (AMG580) is a novel potent, selective phosphodiesterase 10A (PDE10A) inhibitor with IC50 of 0.13 nM. |
|
| DC9457 | AMG 837 (calcium hydrate) | AMG 837 calcium hydrate is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. |
|
| DC6310 | AMG 853(AMG853;Vidupiprant) | AMG 853 is novel a CRTH2 and DP Dual Antagonist. |
|
| DC20660 | AMG-076 | AMG-076 is a potent, selective, non-peptide antagonist of MCHR1 (Melanin-concentrating hormone receptor 1) with binding IC50 of 0.6 nM, with dramatically reduced hERG liability (IC50>5 uM). |
|
| DC8514 | AMG-1 Featured | AMG-1 is a potent inhibitor of human c-Met and RON with IC50 values of 4 and 9 nmol/L respectively. |
|
| DC20661 | AMG-1694 | AMG1694 is a potent, small molecule Glucokinase (GK)-GKRP (GK regulatory protein) disruptor, does not block the GK binding site directly. |
|
| DC9793 | AMG232 | AMG232 is a potent, selective and orally bioavailable inhibitor of MDM2−p53 interaction with IC50 value of 9.1 nM in EdU cells . |
|
| DC23850 | AMG-458(AMG458;AMG 458) | AMG-458 (AMG458) is a potent, selective, orally bioavailable c-Met inhibitor with Ki of 1.2 nM (human c-Met). |
|
| DC20664 | AMG-548 Featured | AMG-548 is a potent and selective inhibitor of p38α with Ki of 0.5 nM, dispalys weak inhibition for p38β (Ki=3.6 nM), and >5,000-fold selectivity over p38γ and p38δ; shows >1,000-fold selectivity over other 36 kinases, and is efficacious in acute and chro |
|
| DC11878 | AMG-579 | AMG-579 is a potent, selective, CNS penetrant, orally bioavailable PDE10A inhibitor with IC50 of 0.1 nM. |
|
| DC12430 | AMG7703 | AMG7703 (4-CMTB, AMG-7703) is an allosteric, selective agonist of FFAR2 (GPR43).. |
|
